Good morning and welcome to Markets Desk, your midday read on the stories moving markets right now.
In the semiconductor space, ASML is drawing fresh scrutiny as China's homegrown deep ultraviolet lithography machines inch closer to commercial viability. Analysts are largely dismissing the near-term threat, arguing Chinese DUV technology remains years behind ASML's installed base and that the stock's recent dip may represent a buying opportunity for patient investors.
Shifting to biotech, several names hit fifty-two week highs on Tuesday, with Incyte leading the charge after posting second quarter results that cleared the bar. The sector has been building momentum through the summer, and Incyte's print gave traders a concrete catalyst to extend those gains, pushing the broader biotech index into constructive territory.
And over in Japan, Tokyo Electric Power narrowed its net loss in the first quarter, but the headline number masks a deteriorating operating picture. Despite stronger sales growth, the utility slipped into an operating loss compared to a profit in the year-ago period, raising questions about cost pressures and whether management can translate revenue gains into sustainable margins ahead of the second half.
That's the tape. Markets Desk, signing off the floor.
